Tenax Therapeutics, Inc. (TENX)
Healthcare · Biotechnology · NASDAQ · US
$1.87+0.54%Close
BUYRECOVERY · day 7
$1.87+0.54%
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $32M
- Beta
- 0.93
- P/E (TTM)
- -1.30
- Short % float
- 43.45%
- Days to cover
- 2.4
- SI change
- +30.5%
- 1W
- -5.56%
- 1M
- -4.10%
- vs SPY 1W
- -6.72%
- vs SPY 1M
- -7.09%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Director Buys $101,760.00 in Stock
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Tenax Therapeutics' heart drug misses main goal in study, shares plunge
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
